Viewing data from:

VENLAFAXINE BESYLATE

NDA

VENLAFAXINE BESYLATE | N215429 | ALMATICA PHARMA LLC

1 strength1 unique patent0 unique exclusivities

Patent Timeline

1 unique patent by expiration date

Active (1)Today

2027

2028

Today

May. 16, 2028

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Medicare Part D Spending

CMS annual spending data for Venlafaxine Besylate ER (2023)

Total Spending

$434K

Total Claims

1,459

Beneficiaries

447

Avg Cost/Unit

$6.73

Spending Trend

$40K(2022)→$434K(2023)

YoY Change:+3.3%

5yr CAGR:+3.3%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Approval Letters

3 letters from Drugs@FDA

Source: Drugs@FDA application documents.

Products (1)

#001 — EQ 112.5MG BASE

RLD

1 patent0 exclusivities▴

TABLET, EXTENDED RELEASE;ORAL | Approved: Jun 29, 2022

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
7776358	May 16, 2028	—	—	Yes	—	—